DJO Incorporated (DJO) Receives FDA Approval for Supplement to Company's Existing Pre-Market Approval
DJO Incorporated (NYSE: DJO) has received FDA approval for a supplement to the Company's existing Pre-Market Approval (PMA). The PMA supplement covers several new product features that are built into the control modules for its Combined Magnetic Field (CMF) OL1000 and SpinaLogic® bone growth stimulation product lines. The new product features enhance patients' ease of use.
The CMF OL1000 and SpinaLogic® devices are the only bone growth stimulation devices utilizing the unique and patented CMF technology. CMF is the only waveform clinically proven to stimulate bone growth from a simple 30 minute per day treatment with FDA-indicated use in both long bone and primary lumbar Spine applications.
The CMF OL1000 and SpinaLogic® devices are the only bone growth stimulation devices utilizing the unique and patented CMF technology. CMF is the only waveform clinically proven to stimulate bone growth from a simple 30 minute per day treatment with FDA-indicated use in both long bone and primary lumbar Spine applications.
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary Endpoint; to Move Forward with End of Phase Meeting
- Auxilium Pharma (AUXL), Glaxo (GSK) Enter Testim 1% Co-Promotion Agreement
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
